PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Loading...
Embargo End Date
ICR Authors
Authors
Dillon, MT
Boylan, Z
Smith, D
Guevara, J
Mohammed, K
Peckitt, C
Saunders, M
Banerji, U
Clack, G
Smith, SA
Spicer, JF
Forster, MD
Harrington, KJ
Boylan, Z
Smith, D
Guevara, J
Mohammed, K
Peckitt, C
Saunders, M
Banerji, U
Clack, G
Smith, SA
Spicer, JF
Forster, MD
Harrington, KJ
Document Type
Journal Article
Date
2018-08-01
Date Accepted
2018-06-06
Abstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Citation
Clinical and translational radiation oncology, 2018, 12 pp. 16 - 20
Source Title
Publisher
ELSEVIER IRELAND LTD
ISSN
2405-6308
eISSN
2405-6308
Research Team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Targeted Therapy
Medicine Drug Development Unit (de Bono)
Targeted Therapy